Professor Leary retired from Purdue in August, 2015 and became Professor Emeritus. He subsequently moved to Santa Fe, New Mexico in September, 2015 where he continues to write and review manuscripts for a number of scientific journals and to serve regularly on NIH Study Sections.
He has also recently started his own consulting/prototyping company "Aurora Life Technologies, LLC" at http://auroralifetechnologies.com) in the areas of biomedical instrumentation and applications, particularly in the area of point-of-care diagnostic devices. The company designs and invents customized new technologies for client businesses, solves difficult scientific and engineering problems, and can build and test experimental prototypes under contract. It serves customers around the world communicating either over the Internet or coming directly to their work sites to meet with their employees. Dr. Leary has more than 40 years' experience in flow cytometry and cell sorting, and for the past 10 years, microfluidic cytometry experience for point-of-care portable devices.
He has also recently started his own consulting/prototyping company "Aurora Life Technologies, LLC" at http://auroralifetechnologies.com) in the areas of biomedical instrumentation and applications, particularly in the area of point-of-care diagnostic devices. The company designs and invents customized new technologies for client businesses, solves difficult scientific and engineering problems, and can build and test experimental prototypes under contract. It serves customers around the world communicating either over the Internet or coming directly to their work sites to meet with their employees. Dr. Leary has more than 40 years' experience in flow cytometry and cell sorting, and for the past 10 years, microfluidic cytometry experience for point-of-care portable devices.
This will count as one of your downloads.
You will have access to both the presentation and article (if available).
Microfluidic cytometry also requires judicious use of small sample volumes and appropriate statistical sampling by microfluidic cytometry or imaging for adequate statistical significance to permit real-time (typically in less than 15 minutes) initial medical decisions for patients in the field. This is not something conventional cytometry traditionally worries about, but is very important for development of small, portable microfluidic devices with small-volume throughputs. It also provides a more reasonable alternative to conventional tubes of blood when sampling geriatric and newborn patients for whom a conventional peripheral blood draw can be problematical. Instead one or two drops of blood obtained by pin-prick should be able to provide statistically meaningful results for use in making real-time medical decisions without the need for blood fractionation, which is not realistic in the doctor’s office or field.
Microfluidic cytometry requires judicious use of small sample volumes and appropriate statistical sampling by microfluidic cytometry or imaging for adequate statistical significance to permit real-time (typically < 15 minutes) medical decisions for patients at the physician’s office or real-time decision making in the field. One or two drops of blood obtained by pin-prick should be able to provide statistically meaningful results for use in making real-time medical decisions without the need for blood fractionation, which is not realistic in the field.
Both an FDA-approved therapeutic, hydralazine, and natural product, epigallocatechin gallate, were explored as antioxidants for acrolein with nanoparticles for increased efficacy and stability in neuronal cell cultures. Not only were the nanoparticles explored in neuronal cells, but also in a co-cultured in vitro model with microglial cells to study potential immune responses to near-infrared (NIRF)-labeled nanoparticles and uptake. Studies included nanoparticle toxicity, uptake, and therapeutic response using fluorescence-based techniques with both dormant and activated immune microglia co-cultured with neuronal cells.
A microfabricated microfluidic bioMEMS device to model human brain aneurisms: the aneurysm-on-a-chip
Multicolor flow cytometric analyses were performed on a BD FACS Aria III. Human leukemic stem cell-like cell RS4;11 (with putative immunophenotype CD133+/CD24+/-, CD34+/-, CD38+, CD10-/Flt3+) was spiked into normal hematopoietic stem-progenitor cells obtained from a “buffy coat” prep (with putative immunophenotype CD133- /CD34+/CD38-/CD10-/Flt-3-) to be used as a model human leukemia patient. To analyze the model system, digital data mixtures of the two cell types were first created and assigned classifiers in order to create truth sets. ROC (Receiver Operating Characteristic) and multidimensional cluster analyses were used to evaluate the specificity and sensitivity of the immunophenotyping panel and for automated cell population identification, respectively. Costs of misclassification (false targeting) were also accounted for by this analysis scheme. Ultimately, this analysis scheme will be applied to use of nanoparticle-antibody conjugates at therapeutic doses for targeted killing of leukemia stem cells preferentially to normal stem –progenitor cells.
Application of advanced cytometric and molecular technologies to minimal residual disease monitoring
This will count as one of your downloads.
You will have access to both the presentation and article (if available).
View contact details
No SPIE Account? Create one
